Wave Life Sciences (WVE) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Strategic platform and pipeline evolution

• Positioned at a strategic inflection point in 2026, advancing platform chemistry into meaningful therapies, notably WVE-007 for inhibin E, with phase II-A high BMI studies starting soon.

• RNA editing platform is progressing, led by alpha-1 antitrypsin deficiency (AATD), with regulatory engagement this summer for potential accelerated approval and WVE-008 for PNPLA3 entering the clinic by year-end.

• Platform leverages chemistry to unlock high-value genetic targets, enabling translation of clinical genetics into therapies for diseases like obesity and liver disorders.

• Differentiation is driven by unique chemistry, enabling dual modalities such as silencing and upregulation within a single molecule, with further details to be shared at an upcoming R&D day.

WVE-007 (inhibin E) program insights

• Inhibin E is a genetically validated target for obesity and cardiometabolic disease, with human data showing reduced visceral fat, improved lean mass, and lower lipid levels.

• Preclinical and phase I data show single-dose reductions in body weight and fat, with muscle preservation and potential for combination and maintenance therapy with incretins.

• Phase I healthy volunteer study demonstrated 15% visceral fat reduction, 5.4% subcutaneous fat reduction, and 3.3% waist circumference decrease.

• Unique chemistry enables best-in-class siRNA performance, with improved potency, durability, and infrequent dosing (once or twice yearly).

• Phase II-A will target high BMI patients with comorbidities, using MRI and DEXA endpoints, and explore dose optimization and broader cardiometabolic impacts.

Broader metabolic and combination opportunities

• WVE-007 is positioned for use in obesity, diabetes, MASH, and other cardiometabolic diseases, with embedded biomarker analysis to unlock further indications.

• Upcoming studies include combination with incretins and maintenance therapy to prevent weight regain after incretin cessation.